Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, raised $6 million by offering 1.2 million units at $4.75, as expected. The company offered 0.3 million fewer units than expected. Each unit...read more
Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, lowered the proposed deal size for its upcoming Nasdaq IPO on Monday. In its latest filing, the company also changes the security type offered to...read more
Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, announced terms for its IPO on Tuesday. The East Setauket, NY-based company plans to raise $9 million by offering 1.5 million shares at a...read more
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more
Micro-cap oncology biotech Lixte Biotechnology prices Nasdaq uplisting at $4.75
Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, raised $6 million by offering 1.2 million units at $4.75, as expected. The company offered 0.3 million fewer units than expected. Each unit...read more
Micro-cap oncology biotech Lixte Biotechnology lowers deal size, now offering units in $7 million Nasdaq uplisting
Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, lowered the proposed deal size for its upcoming Nasdaq IPO on Monday. In its latest filing, the company also changes the security type offered to...read more
Micro-cap oncology biotech Lixte Biotechnology sets terms for $9 million Nasdaq uplisting
Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, announced terms for its IPO on Tuesday. The East Setauket, NY-based company plans to raise $9 million by offering 1.5 million shares at a...read more
US IPO Weekly Recap: The September IPO market kicks off with a quiet week
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more